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Abstract 
The competitive binding to α1-acid glycoprotein of a dynamically racemic 
europium(III) complex with seven pharmacologically active drugs absorbing in the 
range 250 to 290 nm, has been monitored by following changes in europium total 
emission and in  induced circularly polarised luminescence (CPL). Binding affinities 
corresponding to Kd values in the range 0.5 to 100µM were measured, in good 
agreement with literature data.     
 
Keywords europium; luminescence; CPL;  drug binding; chirality 
 
Introduction 
 
Alpha-1-acid glycoprotein (α1-AGP) is an important glycoprotein found in the 
plasma. It has a molecular weight of 41-43 kDa and comprises a single chain of 183 
amino acids, with five N-linked oligosaccharides (glycans). 1 The carbohydrate 
content makes up 45% of the protein’s total molecular weight.  It is an acute-phase 
protein and the blood plasma concentration of the protein increases in response to 
inflammation. α1-AGP has a normal plasma concentration between 0.6-1.2 mg/mL, 
representing 1-3% of the total blood plasma protein concentration. Following an acute 
phase reaction (e.g. stress, inflammation, burn or infection), the α1-AGP concentration 
in blood can increase up to 400% from its normal concentration. 
 It exists as a mixture of two or three genetic variants. 1 Two genetic polymorphs are 
the A and the major (70%) F1S variants; in the A variant, 22 amino acids out of 183 
residues differ from the F1S polymorph. The differences in structure of the 
polymorphs translate into slightly different drug binding properties. For example,  α1-
AGP has an isoelectric point (pI) of 2.7-3.0, and predominantly binds to neutral and 
basic drugs2-5 such as  methadone, 2 chlorpromazine and disopyramide. 3,4  
A wide range of drugs is known to bind to α1-AGP. Increased binding of 
pharmacologically active drugs to α1-AGP moderates their clinical effect, due to 
decreased levels of unbound drug in the bloodstream. Such behaviour has important 
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clinical ramifications, for example in anaesthesia duration and in determining dosage 
for drug therapy. Representative examples of such drugs that bind to α1-AGP (Fig. 1), 
include the heroin substitute, methadone, 6 the important tyrosine kinase inhibitor 
Imatinib 7 (or Gleevec) used successfully to treat chronic myelogeneous leukaemia, 
disopyramide- an anti-arrythmic agent used to treat ventricular tachycardia,8  common 
anaesthetics, such as lidocaine and bupivacaine, 9,10 and various tricyclic anti-
depressants,  such as nortriptyline and imipramine. 9,11   
 
    
   
Figure 1.   Selected drugs known to bind to α1-AGP 
 
The racemic europium complex [Eu.L1(OH2)]+ ,  (Scheme 1), has been shown to bind  
reversibly to α1-AGP {logK = 5.73 (0.06)}.1,13  Addition of α1-AGP to [Eu.L1(OH2)]+ 
caused displacement of the bound water molecule and gave rise to major changes in 
the intensity and form of the europium emission spectrum, consistent with a 
significant change in the coordination environment, notably involving loss of the axial 
donor ligand. It was hypothesised that coordination of the side-chain carboxylate of 
the protein Glu-64 residue had occurred, 1 consistent with structural alignment studies 
highlighting the presence of 3 proximate glutamate residues (Glu-35, 36 and 64 – the 
nearest one) in the main drug binding site of α1-AGP. 
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The electronic circular dichroism (ECD) spectra of [Eu.L1(OH2)]+ in the absence and 
presence of one equivalent of α1-AGP showed two major bands at 290 and 340 nm 
with negative Cotton effects, typical of a well-defined coordination environment. 
Each transition possessed fine structure with two bands evident, which suggests that 
the two azaxanthone ligands are in different but rigid local environments.  Such 
observations led to the prediction that one azaxanthone ligand had dissociated from 
the metal centre and was included in the hydrophobic protein binding cavity, whilst 
the other remained coordinated to europium,  (Scheme 1). The incremental addition of 
chlorpromazine to the protein-bound adduct, [Eu.L1.AGP], caused a decrease in the 
induced ECD of the azaxanthone chromophore, consistent with reversible binding of 
[Eu.L1(OH2)]+ to α1-AGP, and competitive binding of chlorpromazine with the 
complex. 
 
 
      Scheme 1.  Reversible binding of the complex to α1-AGP  
 
Binding to α1-AGP was characterized by a switching on of a large induced europium 
circularly polarized luminescence (CPL). 12 The parent complex is dynamically 
racemic and shows no CPL. The protein bound form creates a chiral environment in 
which a large CPL signal is induced, following selective formation of the chiral 
adduct.   The binding behaviour allowed the concentration of α1-AGP to be assessed 
directly in serum samples. The emission changes were calibrated to read protein 
concentration directly and compared very favourably to independent ELISA assays. 12  
 
The CPL technique has many advantages when studying chiral systems, notably its 
high sensitivity in comparison to other chiroptical techniques, such as electronic 
circular dichroism. The development of lanthanide complexes as CPL probes has 
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gained momentum recently, as much brighter chiral complexes have been discovered. 
Large gem values characterize the chiroptical behavior of  these complexes, with gem 
being described by equation 1. 13 
 𝑔!" 𝜆 = !!!(!)!! ! !!!(!)     (1) 
 
The long-lifetime of the luminescence allows the lanthanide complex to be observed 
selectively using time-gating. The emissive state of the lanthanide is also highly 
sensitive to the coordination environment of the complex, so changes due to 
reversible binding of different ligands can be observed, made simpler by the 
separation of the left and right-handed polarised light intensity. Thus far, many of the 
reported examples of lanthanide CPL probes have been qualitative rather than 
quantitative descriptors, showing a response of either an induced CPL signal or the 
loss of one. They have, however, been used in a variety of ways. Some examples take 
advantage of the chirality in the ligand to induce a CPL signal. Examples include the 
use of naturally chiral molecules such as sugars to achieve this. 13c Others, such as 
that shown in Scheme 1, bind to proteins which enforces the complex to adopt a 
preferred low-energy conformation, and hence a strong CPL signal is induced. 12 
 
With this background in mind, the range of drugs shown above (Figure 1) presents an 
ideal set of compounds to examine the competitive binding to α1-AGP of the drug and 
the europium complex. Each drug does not absorb above 320 nm allowing the Eu 
complex to be addressed by selective excitation into the azaxanthone chromophore, 
permitting sensitized emission.  The binding affinity of the Eu complex for AGP (log 
K = 5.7) falls in the range of reported AGP binding constants for each of these 
systems (log K values range from 4.3 to 6.4). 6-11 Accordingly, we report that CPL can 
be used to assess quantitatively drug binding to a protein. The values obtained by CPL 
have been compared to those assessed by ratiometric analysis of total emission 
spectral changes.  The use of CPL to monitor binding quantitatively either to the 
metal centre or via interaction of the ligand is relatively rare. 13    
Results and Discussion 
The competitive binding of selected drugs (Figure 1) to the pre-formed complex, 
[Eu.L1.AGP], was monitored by studying the spectral changes in the total and CPL 
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emission. Each titration was set up and carried out in the same manner. The free 
complex (30 µM) was dissolved in aqueous NaCl solution (1 mL, 0.1 M) and α1-AGP 
was added to the solution to give a 1:1 (complex:AGP) ratio. The pH was adjusted to 
7.4 and initial emission and CPL spectrum were acquired. Incremental additions of 
the drug were made, maintaining the pH at 7.4 (I = 0.1 NaCl; 295K). Each titration 
was halted after ten equivalents of the drug had been added ([drug] = 300 µM) and the 
final emission and CPL spectra were recorded. The total emission intensity reduced in 
magnitude and the significant changes in spectral form permitted ratiometric analysis 
to be undertaken, measuring the change in the ΔJ =2/ΔJ =1 intensity ratio as a 
function of the concentration of added drug, (Table 1).  Parallel experiments were 
attempted with the terbium analogue, 14 but the protein-bound complex was 
significantly more quenched by charge transfer, and the less strong observed emission 
signal -in both CPL and total emission- precluded detailed quantitative studies.  
Table 1. Selected physicochemical data and estimated apparent binding constants 
(0.1 M NaCl, pH 7.4) for pharmaceuticals binding to native α1-AGP.  
 
Pharmaceutical pKa λmax/nm log K 
c 
(tot. emission) 
log K b  
(CPL) 
log K a 
(literature) 
(±)Methadone 8.94 270 5.34(05) 5.35(04) 5.6 
(±)Bupivacaine 8.21 263 4.77(05) 5.38(03) 5.7 
S-Bupivacaine 8.21 263 5.41(04) 5.46(04) 5.4 
Imatinib 8.27 292 5.82(06) 5.77(04) 
 
6.4 
(±)Disopyramide 10.4 254 5.55(05) 4.99(02) 5.6 
Imipramine 9.50 250 4.18(02) 4.90(04) 4.9 
Nortriptyline 10.1 240 3.60(01) 4.44(04) 4.5 
Lidocaine 8.19 263 4.31(03) 4.38(04) 4.4 
a values were taken from literature references, referring to the native protein where possible 6-
11;  b CPL data were analysed by plotting (ΔImax–ΔI) as a function of added drug 
concentration;  c errors quoted here refer to statistical data fitting analysis only; data analysis 
related to changes in the ratio of the europium  ΔJ =2/ΔJ =1  emission intensity  as a function 
of added drug (see ESI).  
 
Overall, the most significant changes occurred in the hypersensitive ΔJ = 2 and ΔJ = 4 
manifolds.  In parallel, the reduction in the CPL emission intensity at 621 nm was 
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plotted as a function of drug concentration. (Figures 1-3; Table 1 and SI).  The CPL 
intensity variation was also assessed at 613 nm and gave near identical data, within 
the estimated error. Binding isotherms derived from CPL and total emission data were 
analysed assuming a 1:1 binding stoichiometry for the interaction of the drug at the 
major AGP binding site; such a stoichiometry is consistent with literature precedent. 6-
11   
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Figure 1. Variation in the total emission (upper) and CPL profile (lower) of 1:1 (Eu 
complex:AGP) upon addition of 0 to 300 µM racemic bupivacaine (left) and S-bupivacaine 
(right) (30 µM complex, 30 µM AGP, 295 K, pH 7.4, 0.1 M NaCl).  
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The binding of the drug to α1-AGP first involves the dissociation of the complex from 
the protein binding site, followed by association of the drug into the binding pocket. 
The europium CPL and total emission changes provide information on the first 
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Figure 2. Competitive binding plots of [(IL-IR)max – (IL-IR)] (621 nm) vs. concentration for 
bupivacaine (left) and S-bupivacaine (right) (30 µM complex, 30 µM AGP, 295 K, pH 7.4, 0.1 
M NaCl). (Bupivacaine limiting values: LVmin = 0, LVmax = 1.3) (S-bupivacaine limiting values: 
LVmin = 0, LVmax = 1.0) 
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Figure 3.   Left: variation in the CPL profile of 1:1 (Eucomplex:AGP) upon addition of 0 to 300 
µM lidocaine. Right: competitive binding plot of [(IL-IR )max – (IL-IR)] (at 621 nm) vs. 
concentration of lidocaine (30 µM complex, 30 µM AGP, 295 K, pH 7.4, 0.1 M NaCl). 
(Lidocaine limiting values: LVmin = 0, LVmax = 1.1)  
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dissociative step only. The CPL data set relates to the change in concentration of the 
most emissive chiral species, whereas the total emission changes report on the 
weighted sum of all emissive Eu species, in proportion to their brightness and mole 
fraction. Nevertheless, the determination of these apparent binding constant values 
gives insight into the relative affinity of the drug molecule to α1-AGP, allowing a 
comparison with literature data. Such published data were often obtained by 
monitoring the small changes in the protein CD that accompany drug binding.  
Each titration was repeated twice and an average value is given.  The main source of 
error in the CPL experimental data can be traced to the CPL detector response, in 
which the signal is only reliable when it is five times larger than the background 
noise. However, the quoted error on the binding constants derives from the fitting 
function, and so is an underestimate of the true error. 
 
Figure 4.    Competitive binding plot of [(IL-IR )max – (IL-IR)] (at 613 nm) vs. concentration of 
Imatinib (left) and methadone (right), (30 µM complex, 30 µM AGP, 295 K, pH 7.4, 0.1 M 
NaCl).   
Summary   
Drug binding to a protein has been studied quantitatively for the first time, using 
changes in circularly polarized luminescence.  For the series of anaesthetics, lidocaine 
bound most weakly, and there was evidence from the total emission behaviour that S-
bupivacaine bound more strongly than the racemate. Levobupivacaine is the (S)-
enantiomer of bupivacaine and a similar apparent binding constant to native AGP was 
calculated in each case, although the literature binding constant to AGP is reported to 
be slightly higher for racemic bupivacaine than for the S enantiomer (log K = 5.72 vs 
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5.43). 10b,10c  However, another  study has suggested that S-bupivacaine has a higher 
affinity towards the F1S variant of AGP than racemic bupivacaine, with logK values 
of 5.84 (± 0.02) and 5.52 (± 0.03) respectively. The F1S variant normally constitutes 
70% of the total AGP, and so usually is the more important to consider.14 Therefore, 
some caution needs to exercised in interpreting these data. 10a Of the remaining 
systems analysed, imipramine bound more strongly than the related nortriptyline, 
whilst the more hydrophobic imatinib, bound most strongly, in accord with literature 
binding data.  
Conclusions 
 
The competitive binding to α1-acid glycoprotein of the selected pharmacologically 
active compounds can be assessed quickly and easily by observing the total emission 
and CPL spectral changes of the chiral Eu(III) complex, [Eu.L1]+ .  Such information 
is important for dosage and treatment protocols, as the fraction of free and bound drug 
in vivo will depend on the concentration of AGP in serum, and this varies in a variety 
of disease states, notably in infection and inflammation.  Given that related Eu(III) 
complexes have been used to monitor analytes like citrate, lactate and urate 16 in a 
wide range of bio-fluids, using relatively cheap instrumentation, such sensitive 
luminescence methods offer scope for development. Moreover, alpha-1-acid 
glycoprotein itself has been identified, following a study on17,345 patients, as one of 
only four key circulating ‘biomarkers’, that can be used to estimate the five-year risk 
of “all-cause” mortality.  Indeed, α1-AGP was stated to be ‘the strongest multivariate 
predictor of the risk of death from all causes’. The other three biomarkers are citrate, 
albumin and the particle size of very low density lipoprotein.  17 
 
Experimental 
The Eu complex was prepared as described earlier 12  : [Eu.L1(H2O)]+  m/z (HRMS+) 
855.1797 [M]+
 
(C38H36EuN6O8151Eu requires 855.1816); (HPLC) tR = 4.8 min; λmax 
(H2O) 336 nm. 
HPLC analysis 
Reverse-phase preparative HPLC used to purify the Eu complex was performed at 
295 K using a Shimadzu system consisting of a Degassing Unit (DGU-20A5R), a 
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Prominence Preparative Liquid Chromatograph (LC-20AP), a Prominence UV/Vis 
Detector (SPD-20A) and a Communications Bus Module (CBM-20A). An XBridge 
C18 OBD 19 x 100 mm, i.d. 5 µM column was used with a flow rate of 2 mL/min 
(analytical) or 17 mL/min (prep). The solvent system was H2O +0.1% formic acid / 
MeOH +0.1% formic acid (gradient elution, see Table 2). The UV detector was set at 
336 nm and fraction collection was performed manually. 
Table 2   HPLC conditions used for the purification of [Eu.L1(H2O)]+.  
Step Time / min Flow (Analytical/Prep)  / 
mL min-1 
%H2O    
(0.1% FA) 
%MeOH 
(0.1% FA) 
0 0.0 2.0 / 17.0 90.0 10.0 
1 10.0 2.0 / 17.0 5.0 95.0 
2 13.0 2.0 / 17.0 5.0 95.0 
3 13.5 2.0 / 17.0 90.0 10.0 
4 16.5 2.0 / 17.0 90.0 10.0 
 
Optical methods All samples for optical analyses were contained in quartz cuvettes 
with a path length of 1 cm and a polished base. Measurements were recorded at 295 
K.  UV-Vis absorbance spectra were recorded on an ATI Unicam UV/Vis 
spectrometer (Model UV2) using Vision version 3.33 software. Samples were 
measured relative to a reference of pure solvent contained in a matched cell. Emission 
spectra were recorded on an ISA Joblin-Yvon Spex Fluorolog-3 luminescence 
spectrometer using DataMax v2.2.10 software. An integration time of 0.5 seconds and 
increment of 0.5 nm were used. Lifetime measurements were carried out on a Perkin 
Elmer LS55 spectrometer using custom written software. The Ln3+ ion was directly 
excited via the chromophore using a short pulse of light at λexc (336 nm for 
[Eu.L1(OH2)]
+), followed by monitoring the integrated intensity of the light emitted at 
a chosen wavelength (612.5 nm for Eu), during a fixed gate time, tg, after a delay 
time, td. Measurements were made for a minimum of 20 delay times, covering more 
than 3 lifetimes. A gate time of 0.1 ms was used and the excitation and emission slits 
were set to 10 nm. The observed decay curves were plotted in Excel using eq. 1.  
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The excited state lifetime, τ, is the inverse of the radiative decay rate constant, k.  
Apparent binding constants were calculated by fitting equation 2 to emission or CPL 
data using OriginTM software and non-linear least squares regression analysis.  
 
 
 
 
(2) 
where [X]: Total concentration of selected analyte in solution ; [Eu]: Total 
concentration of the complex;  K: Binding constant ; F: Either intensity ratio of 
selected emission transitions or IL - IR values;  F0: Initial ratio; F1: Final ratio;   [EuX]: 
The concentration of the analyte-coordination complex;  [Xf]: The concentration of 
free analyte;   [Euf]: The concentration of free complex  
The CPL spectra were recorded on a custom built spectrometer 15 consisting of a laser 
driven light source (Energetiq EQ-99 LDLS, spectral range 170 to 2100 nm) coupled 
to an Acton SP2150 monochromator (600 g/nm, 300 nm Blaze) that allows excitation 
wavelengths to be selected with a 6 nm FWHM band-pass. The collection of the 
emitted light was facilitated (90° angle set up, 1 cm path length quartz cuvette) by a 
Lock-In Amplifier (Hinds Instruments Signaloc 2100) and Photoelastic Modulator 
(Hinds Instruments PEM-90). The differentiated light was focused onto an Acton 
SP2150 monochromator (1200 g/nm, 500 nm Blaze) equipped with a high sensitivity 
cooled Photo Multiplier Tube (Hamamatsu 10723-01 red corrected).  
The detection of the CPL signal was achieved using the field modulation lock-in 
technique. The electronic signal from the PMT was fed into the lock-in amplifier 
(Hinds Instruments Signaloc 2100). The reference signal for the lock-in detection was 
provided by the PEM control unit. The monochromators, PEM control unit and lock-
in amplifier were interfaced with a desktop PC and controlled by Labview code.  
A correction factor for the wavelength dependence of the detection system was 
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constructed using a calibrated lamp (Edmund Optics). The measured raw data was 
subsequently corrected using this correction factor. The validation of the CPL 
detection systems was achieved using light emitting diodes (LEDs) at various 
emission wavelengths. The LED was mounted in the sample holder and the light from 
the LED (650 nm) was fed through a broad-band polarising filter and quarter wave 
plate (Thor Labs) to generate circularly polarised light. Prior to all measurements, this 
technique was used to set the phase of the lock-in amplifier correctly.  Spectra were 
recorded using a 5 spectral average sequence in the range of 570-720 nm (Eu), with 
0.5 nm spectral intervals and using a 500 microsecond integration time.  
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